Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc.

ANIP

0.00

Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ: ANIP) with a Hold and lowers the price target from $91 to $90.